(1)
EUSA Pharma (UK) Limited (
EUSA Pharma ), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network
(NCCN
) for B-Cell Lymphomas to include siltuximab (SYLVANT
) as the preferred primary treatment for patients with human immunodeficiency virus-negative [HIV(-)] and human herpesvirus 8-negative [HHV-8(-)] multicentric Castleman disease (MCD), also known as idiopathic multicentric Castleman disease (iMCD), regardless of histopathologic subtype.
1 Siltuximab is currently approved in more than 40 countries worldwide for the treatment of all histopathologic subtypes of iMCD, a rare, life-threatening and debilitating orphan condition of the lymph nodes and related tissues. 2,3 The update is based on a 2020 publication which demonstrated that there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
New Global Coalition Aims to Eliminate Structural Barriers to Fight Cancer Crisis in Resource-Limited Countries in Africa
Share Article
Collaboration on Implementation Science Research in Global Oncology awards $500,000 to eight country-specific pilot projects in quest to develop sustainable best practices We have to look across the spectrum of cancer care capacity building and select certain projects to pilot in different countries, evaluate how they work and, if we, can replicate them in other countries,” said Ute Dugan, MD, co-founder of CIRGO. CHICAGO (PRWEB) February 09, 2021 A group of global oncology organizations have joined forces to establish the Collaboration on Implementation Science Research in Global Oncology (CIRGO) to improve the coordination of cancer care systems in low- and middle-income countries, particularly in Africa.
Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA
® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11, 3:30 PM-4:15 PM EST).
Share this article
Share this article
RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA
® and ZYTIGA
® plus prednisone (control arm).
1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST).
Cancer care in Bangladesh: A tale of scarcity and negligence
Shahana Akhter, an inhabitant of a remote village of Netrokona district has to wait for hours at NICRH to get an appointment to treat her emaciated mother who has been suffering from colorectal cancer. Hundreds of patients like her were seen lying on the dirty floors and waiting for long hours to receive treatment. The photo was taken on January 31, 2021. Photo: Anisur Rahman
Due to overwhelming treatment costs, scarcity of trained professionals and unavailability of equipment, cancer care is still inaccessible to hundreds of thousands of cancer patients in Bangladesh.